JHEP Reports最新文献

{"title":"Molecular MRI of T-cell immune response to cryoablation in immunologically hot vs. cold hepatocellular carcinoma","authors":"Jessica Gois Santana , Annabella Shewarega , David Nam , James Duncan , David Craig Madoff , Fahmeed Hyder , Daniel Coman , Julius Chapiro","doi":"10.1016/j.jhepr.2024.101294","DOIUrl":"10.1016/j.jhepr.2024.101294","url":null,"abstract":"<div><h3>Background & Aims</h3><div>Increasing enthusiasm around integrating locoregional therapy with systemic immunotherapy in primary liver cancer underscores the need for non-invasive imaging biomarkers. In this study, we aimed to establish advanced molecular MRI tools for monitoring T-cell responses to cryoablation in murine models, distinguishing between immunologically \"hot\" and \"cold\" hepatocellular carcinoma (HCC).</div></div><div><h3>Methods</h3><div>Immunocompetent 7-10-week-old C57BL/6J and BALB/cJ mice (n = 18 each) received carbon tetrachloride for 12 weeks to induce cirrhosis. Intrinsically immunogenic Hepa1-6 (“hot”) and non-immunogenic TiB75 (“cold”) cells were orthotopically implanted into C57BL/6 or BALB/c mice, respectively, to generate focal HCC lesions. After one week, animals were randomly assigned to (A) partial cryoablation (pCryo) (1.2 mm cryoprobe, -40 °C) or (B) no treatment (n = 8 per group and tumor type). Gadolinium 160 (<sup>160</sup>Gd)-labeled CD8<sup>+</sup> antibody was administered intravenously either 1 week after tumor induction (control) or 1-week post (pCryo) (treatment). T1-weighted MRI scans were performed using a 9.4 T MRI scanner. Radiological-pathological correlation included imaging mass cytometry and immunohistochemistry.</div></div><div><h3>Results</h3><div>pCryo-treated Hepa1-6 tumors displayed peritumoral ring enhancement on T1-weighted MRI with <sup>160</sup>Gd-CD8, correlating with imaging mass cytometry signal patterns. Untreated Hepa1-6 tumors lacked such enhancement. Radiological-pathological correlation confirmed significantly increased tumor-infiltrating CD8<sup>+</sup> T lymphocytes in pCryo Hepa1-6 tumors compared with untreated tumors (<em>p</em> <0.001), and a stronger local response compared with systemic lymph nodes (<em>p</em> = 0.0415). Increased T-lymphocyte infiltration was not observed in TiB75 tumors, as indicated by MRI and histopathology.</div></div><div><h3>Conclusion</h3><div>pCryo induced increased T-cell infiltration in Hepa1-6 tumors compared to TiB75 tumors. T1-weighted MRI, following <sup>160</sup>Gd-CD8 antibody administration, reproducibly detected the ablation-induced changes. These findings encourage further investigation of MRI-based molecular imaging biomarkers to assess immune responses to local tumor therapies.</div></div><div><h3>Impact and implications</h3><div>This study successfully established reliable MR-based molecular imaging tools to visualize CD8<sup>+</sup> anti-tumor specific T-cell infiltration following partial cryoablation (pCryo) in murine tumor models. The study's significance lies in advancing our understanding of immune responses within induced cirrhosis and distinguishing between \"hot\" and \"cold\" tumor phenotypes. The findings not only build upon previous proof-of-principle data but also extend this technology to include different immune cell types in hepatocellular carcinoma. The study reveals that pCryo may exert specific effects on","PeriodicalId":14764,"journal":{"name":"JHEP Reports","volume":"7 3","pages":"Article 101294"},"PeriodicalIF":9.5,"publicationDate":"2024-12-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143388260","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Copyright and information","authors":"","doi":"10.1016/S2589-5559(24)00289-1","DOIUrl":"10.1016/S2589-5559(24)00289-1","url":null,"abstract":"","PeriodicalId":14764,"journal":{"name":"JHEP Reports","volume":"6 12","pages":"Article 101285"},"PeriodicalIF":9.5,"publicationDate":"2024-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142743481","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Corrigendum to: ‘Gut Bifidobacterium longum is associated with better native liver survival in patients with biliary atresia’ (JHEP Reports, Volume 6, Issue 7, July 2024, 101090)","authors":"Chee-Seng Lee , Chia-Ray Lin , Huey-Huey Chua , Jia-Feng Wu , Kai-Chi Chang , Yen-Hsuan Ni , Mei-Hwei Chang , Huey-Ling Chen","doi":"10.1016/j.jhepr.2024.101253","DOIUrl":"10.1016/j.jhepr.2024.101253","url":null,"abstract":"","PeriodicalId":14764,"journal":{"name":"JHEP Reports","volume":"6 12","pages":"Article 101253"},"PeriodicalIF":9.5,"publicationDate":"2024-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142743394","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Editorial Board page","authors":"","doi":"10.1016/S2589-5559(24)00287-8","DOIUrl":"10.1016/S2589-5559(24)00287-8","url":null,"abstract":"","PeriodicalId":14764,"journal":{"name":"JHEP Reports","volume":"6 12","pages":"Article 101283"},"PeriodicalIF":9.5,"publicationDate":"2024-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142743392","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Recent advances in systemic therapy for advanced biliary tract cancer: A systematic review and meta-analysis using reconstructed RCT survival data","authors":"Zhihao Li ,&nbsp;Daniel Aliseda ,&nbsp;Owen Jones ,&nbsp;Luckshi Rajendran ,&nbsp;Christian Magyar ,&nbsp;Robert Grant ,&nbsp;Grainne M. O’Kane ,&nbsp;Anna Saborowski ,&nbsp;Gonzalo Sapisochin ,&nbsp;Arndt Vogel","doi":"10.1016/j.jhepr.2024.101290","DOIUrl":"10.1016/j.jhepr.2024.101290","url":null,"abstract":"<div><h3>Background &amp; Aims</h3><div>Gemcitabine/cisplatin (GemCis) was the long-standing first-line treatment for advanced biliary tract cancers (BTCs). Following positive results from the TOPAZ-01 and KEYNOTE-966 trials, immune checkpoint inhibitors (ICIs) combined with chemotherapy are now the standard of care. We aim to compare the efficacy of first-line therapies for advanced BTCs.</div></div><div><h3>Methods</h3><div>Our systematic review included studies from five databases focusing on English-language articles published between January 2010 and June 2024. We included randomized clinical trials (RCTs) that featured GemCis in a treatment arm for treatment-naive adults with advanced BTCs. The primary endpoints were overall survival (OS) and progression-free survival. We conducted a one-stage meta-analysis using reconstructed survival data, Cox-based models, and restricted mean survival time (RMST).</div></div><div><h3>Results</h3><div>After screening 8,797 studies, 17 RCTs were selected, involving a total of 4,584 patients. Of these, 2,140 (46.7%) received GemCis. The majority (68.9%) were diagnosed with intrahepatic or extrahepatic cholangiocarcinoma, and 80% had metastatic disease at the time of treatment. The pooled median OS in the GemCis group was 11.6 months (95% CI 11.3–12.2 months). GemCis plus pembrolizumab (hazard ratio [HR] 0.99, 95% CI 0.98–0.99; <em>p</em> &lt;0.001), GemCis plus durvalumab (HR 0.98, 95% CI 0.97–0.99; <em>p</em> = 0.015), GemCis plus S-1 (HR 0.97 95% CI 0.95–0.99; <em>p</em> &lt;0.001), and GemCis plus nab-paclitaxel (HR 0.98, 95% CI 0.98–0.99; <em>p</em> &lt;0.001) demonstrated superior OS compared with GemCis alone. These combinations also showed increases in RMST by +1.1, +2.5, +2.8, and +2.1 months, respectively. In terms of progression-free survival, GemCis with ICIs (HR 0.91, 95% CI 0.78–0.94; <em>p</em> &lt;0.001), GemCis plus S-1 (HR 0.98, 95% CI 0.96–0.99; <em>p</em> = 0.003), and GemCis plus nab-paclitaxel (HR 0.98, 95% CI 0.97–0.99; <em>p</em> &lt;0.001) also demonstrated superiority, with corresponding RMST increases of +0.7, +1.9, and +2.5 months, respectively.</div></div><div><h3>Conclusions</h3><div>Despite incremental advancements, a breakthrough in advanced BTC treatment remains elusive. Further improvements in treatment efficacy may require biomarker identification to optimize combinational therapies for better patient selection.</div></div><div><h3>Impact and implications</h3><div>This study analyzed recent RCTs, including KEYNOTE-966, TOPAZ-1, NIFE, and SWOG 1815, involving 4,584 patients with advanced biliary tract cancer. A meta-analysis of 17 treatment arms, using reconstructed survival data, confirmed the modest survival benefit of GemCis plus ICIs, supporting its guideline adoption. The findings, however, highlight the need for biomarker identification and better patient selection.</div></div>","PeriodicalId":14764,"journal":{"name":"JHEP Reports","volume":"7 3","pages":"Article 101290"},"PeriodicalIF":9.5,"publicationDate":"2024-11-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143180629","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Primary sclerosing cholangitis–inflammatory bowel disease: Epidemiology, mortality, and impact of diagnostic sequence","authors":"Kristel K. Leung ,&nbsp;Wenbin Li ,&nbsp;Bettina Hansen ,&nbsp;Aliya Gulamhusein ,&nbsp;Lauren Lapointe-Shaw ,&nbsp;Abdel Aziz Shaheen ,&nbsp;Amanda Ricciuto ,&nbsp;Eric I. Benchimol ,&nbsp;Jennifer A. Flemming ,&nbsp;Gideon M. Hirschfield","doi":"10.1016/j.jhepr.2024.101272","DOIUrl":"10.1016/j.jhepr.2024.101272","url":null,"abstract":"&lt;div&gt;&lt;h3&gt;Background &amp; Aims&lt;/h3&gt;&lt;div&gt;Primary sclerosing cholangitis (PSC) carries significant morbidity and mortality compared with inflammatory bowel disease (IBD). We characterized epidemiology trends and outcomes in those with PSC-IBD and IBD, paying particular attention to the impact of PSC-IBD diagnostic sequence on outcomes.&lt;/div&gt;&lt;/div&gt;&lt;div&gt;&lt;h3&gt;Methods&lt;/h3&gt;&lt;div&gt;Incidence and prevalence of PSC-IBD and IBD (2002–2018) were evaluated using validated health administrative data-derived cohorts from Ontario, Canada (population ∼15 million). Transplant and death outcomes were assessed, with PSC-IBD diagnostic sequence as the exposure of interest.&lt;/div&gt;&lt;/div&gt;&lt;div&gt;&lt;h3&gt;Results&lt;/h3&gt;&lt;div&gt;Incidence of PSC-IBD and IBD was 0.46 and 24.6/100,000 person-years (PYs) respectively, whereas prevalence was 5.53 and 588/100,000 PY respectively. Incidence/prevalence of PSC-IBD increased over time, unlike for IBD. Age at IBD diagnosis was earlier among those with PSC-IBD compared with those with IBD alone. Higher socioeconomic status associated with high PSC-IBD incidence rates and fastest incidence rise. Those diagnosed with IBD before PSC had higher risk of transplant/death compared with PSC before IBD (hazard ratio [HR] 1.34, 95% CI 1.02–1.75), driven by an increased risk of death (HR 2.73, 95% CI 1.68–4.45). PSC-IBD had a 4.5-fold greater risk of transplant/death compared with IBD alone. Liver-related and luminal gastrointestinal disease, particularly hepatopancreatobiliary malignancy, were predominant causes of death among those with PSC-IBD, while cardiovascular and respiratory diseases were predominant among those with IBD.&lt;/div&gt;&lt;/div&gt;&lt;div&gt;&lt;h3&gt;Conclusions&lt;/h3&gt;&lt;div&gt;Population-level data support distinct epidemiological patterns among people living with PSC-IBD compared with IBD, including a higher socioeconomic status and worse outcomes in those found to have IBD before PSC.&lt;/div&gt;&lt;/div&gt;&lt;div&gt;&lt;h3&gt;Impact and implications:&lt;/h3&gt;&lt;div&gt;Individuals with primary sclerosing cholangitis (PSC) face increased morbidity and mortality compared with the general population and those with inflammatory bowel disease (IBD); yet, most individuals with PSC are found to have concomitant IBD during their lifetime. This study describes the distinctive epidemiological differences and mortality trends at the population level between PSC-IBD and IBD. While PSC-IBD remains a rare condition, diagnoses are on the rise (particularly among higher socioeconomic status populations), with most patients being diagnosed with IBD before PSC; this group also experienced higher mortality post-PSC diagnosis compared with those diagnosed with PSC first, with a large proportion of deaths caused by liver- and gut-related causes. Practical applications of these findings include further studies to evaluate whether earlier identification of PSC-IBD affects disease outcomes, as well as educating patients, clinicians, and policymakers on the importance of recognizing PSC-IBD as a distinct entity from IBD a","PeriodicalId":14764,"journal":{"name":"JHEP Reports","volume":"7 3","pages":"Article 101272"},"PeriodicalIF":9.5,"publicationDate":"2024-11-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143428712","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Should all pediatric patients with type 1 autoimmune hepatitis be screened for inflammatory bowel disease?","authors":"Richard Kellermayer","doi":"10.1016/j.jhepr.2024.101291","DOIUrl":"10.1016/j.jhepr.2024.101291","url":null,"abstract":"","PeriodicalId":14764,"journal":{"name":"JHEP Reports","volume":"7 3","pages":"Article 101291"},"PeriodicalIF":9.5,"publicationDate":"2024-11-29","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143437464","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Phase II study with sorafenib plus radiotherapy for advanced HCC with portal and/or hepatic vein tumor thrombosis","authors":"Yirui Zhai ,&nbsp;Liming Wang ,&nbsp;Hong Zhao ,&nbsp;Fan Wu ,&nbsp;Lingxia Xin ,&nbsp;Feng Ye ,&nbsp;Wei Sun ,&nbsp;Yan Song ,&nbsp;Lijuan Niu ,&nbsp;Huiying Zeng ,&nbsp;Jingbo Wang ,&nbsp;Yuan Tang ,&nbsp;Yongwen Song ,&nbsp;Yueping Liu ,&nbsp;Hui Fang ,&nbsp;Ningning Lu ,&nbsp;Hao Jing ,&nbsp;Shunan Qi ,&nbsp;Wenwen Zhang ,&nbsp;Shulian Wang ,&nbsp;Bo Chen","doi":"10.1016/j.jhepr.2024.101287","DOIUrl":"10.1016/j.jhepr.2024.101287","url":null,"abstract":"<div><h3>Background &amp; Aims</h3><div>Portal and hepatic vein tumor thrombosis is associated with inferior outcomes in patients with hepatocellular carcinoma (HCC), and systemic treatment alone is often insufficient. This phase II trial evaluated the efficacy and safety of combining sorafenib with radiotherapy in advanced HCC with thrombosis.</div></div><div><h3>Methods</h3><div>Registered at <span><span>ClinicalTrials.gov</span><svg><path></path></svg></span> (NCT03535259), this phase II single-arm prospective trial targeted patients with HCC with portal or hepatic vein tumor thrombosis, liver minus gross tumor volume &gt;700 ml, and Eastern Cooperative Oncology Group Performance Status scores of 0 or 1. Participants underwent 40–66 Gy radiotherapy for the hepatic primary tumor and vein tumor thrombosis, with concurrent oral sorafenib (400 mg twice daily) until disease progression or unacceptable adverse events. The primary endpoint was median overall survival (mOS) and the secondary endpoints included overall response rate (ORR) per Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1 and Modified Response Evaluation Criteria in Solid Tumors (mRECIST), median progression-free survival (mPFS), time to tumor progression (TTP), tumor thrombosis control, and grade ≥3 adverse events.</div></div><div><h3>Results</h3><div>Between May 2018 and January 2020, 86 patients were enrolled with a median radiotherapy dose of 54 Gy (40–65 Gy). At a median follow-up of 17.2 months, mOS, mPFS, and TTP stood at 16.5, 6.1, and 6.8 months, respectively. ORR reached 47.7% and 52.3% per RECIST and mRECIST, respectively. For the tumor thrombosis, 2-year control rates per mRECIST were 93.1%. No grade 5 adverse events were noted, whereas thrombocytopenia (22.1%) and leukopenia (14.0%) were the main grade 3 adverse events.</div></div><div><h3>Conclusions</h3><div>Concurrent sorafenib and radiotherapy is an effective and well-tolerated treatment for patients with HCC with portal or hepatic vein tumor thrombosis.</div></div><div><h3>Impact and implications:</h3><div>Treatment options for patients with hepatocellular carcinoma (HCC) and vascular tumor thrombus are limited. The efficacy and safety of concurrent sorafenib and radiation for HCC with portal or hepatic vein tumor thrombosis has not been elucidated. This phase II trial shows that concurrent sorafenib and radiotherapy is effective and well-tolerated in the treatment of advanced HCC with portal vein or hepatic vein tumor thrombosis.</div></div><div><h3>Clinical trials registration</h3><div>This study is registered at <span><span>ClinicalTrials.gov</span><svg><path></path></svg></span> (NCT03535259).</div></div>","PeriodicalId":14764,"journal":{"name":"JHEP Reports","volume":"7 3","pages":"Article 101287"},"PeriodicalIF":9.5,"publicationDate":"2024-11-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143182321","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Liver transplantation for HBV-related liver disease: Impact of prophylaxis for HBV on HCC recurrence","authors":"Patrizia Burra ,&nbsp;Sara Battistella ,&nbsp;Laura Turco ,&nbsp;Maria Cristina Morelli ,&nbsp;Gabriella Frassanito ,&nbsp;Nicola De Maria ,&nbsp;Luisa Pasulo ,&nbsp;Stefano Fagiuoli ,&nbsp;Clara Di Benedetto ,&nbsp;Maria Francesca Donato ,&nbsp;Bianca Magro ,&nbsp;Duilio Pagano ,&nbsp;Sherrie Bhoori ,&nbsp;Vincenzo Mazzaferro ,&nbsp;Andrea Lauterio ,&nbsp;Luciano De Carlis ,&nbsp;Domenico Forastiere ,&nbsp;Maria Rendina ,&nbsp;Debora Angrisani ,&nbsp;Alfonso Galeota Lanza ,&nbsp;Francesco Paolo Russo","doi":"10.1016/j.jhepr.2024.101278","DOIUrl":"10.1016/j.jhepr.2024.101278","url":null,"abstract":"<div><h3>Background &amp; Aims</h3><div>Conflicting data exist regarding optimal prophylaxis for HBV recurrence (HBV-R) after liver transplantation (LT), particularly in patients with hepatocellular carcinoma (HCC). We assessed current practices for HBV-R prophylaxis in Italy, evaluating rates, risk factors, and the clinical impact of HBV-R and HCC-R.</div></div><div><h3>Methods</h3><div>We performed a multicentric, retrospective study involving 20 Italian LT centers. All patients who underwent LT for HBV-related liver diseases between 2010 and 2021 were included. Logistic regression was used to identify predictors of HBV-R and HCC-R. Survival curves were estimated with the Kaplan-Meier method and compared with the log-rank test.</div></div><div><h3>Results</h3><div>We included 1,205 LT recipients (60.8% with HCC). HBV prophylaxis was prescribed in 99.7% of recipients, mostly with lifelong hepatitis B immunoglobulin+nucleos(t)ide analogues (HBIG+NUCs) (83.9%). Rates of HBV-R were 2.1% and 3.1% in patients transplanted without and with HCC, respectively. Median times from LT were 60 [9.5–77.5] and 5.5 [1–13] months, respectively. Recipients on lifelong HBIG+NUCs experienced lower rates of HBV-R than those in whom HBIG was withdrawn, used only during LT, or in those who received NUCs alone (2.3% <em>vs.</em> 6.2% <em>vs.</em> 1.9% <em>vs.</em> 8%, respectively; <em>p =</em> 0.042). In recipients with HCC, HCC-R rate was 10.8% (median time from LT: 18 months). At multivariate analysis, HBV-R (odds ratio [OR] 10.329; 95% CI 3.665-29.110), Child-Pugh C (OR 3.519; 95% CI 1.305-9.484), and microvascular invasion (OR 3.088; 95% CI 1.692-5.634) were independently associated with HCC-R. Five-year survival was lower in recipients who experienced HCC-R (32.5% <em>vs.</em> 92.4% in those who did not; <em>p &lt;</em>0.001).</div></div><div><h3>Conclusion</h3><div>In Italy, HBV prophylaxis is mostly based on lifelong HBIG+NUCs. HBV-R was rare and not associated with survival in patients transplanted for decompensated cirrhosis. In patients transplanted for HCC, HBV-R was independently associated with HCC-R. The clinical implications of these findings deserve further investigation.</div></div><div><h3>Impact and implications:</h3><div>In Italy, the combination of high-barrier nucleos(t)ide analogues and hepatitis B immunoglobulins remains the most widely used regimen for antiviral prophylaxis following liver transplantation for HBV-related liver disease. Hepatitis B recurrence after liver transplantation is a rare event and not associated with reduced survival. In transplant recipients with hepatocellular carcinoma, HBV recurrence was independently associated with hepatocellular carcinoma recurrence, though this may simply reflect an epiphenomenon without any causal relationship.</div></div>","PeriodicalId":14764,"journal":{"name":"JHEP Reports","volume":"7 3","pages":"Article 101278"},"PeriodicalIF":9.5,"publicationDate":"2024-11-23","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143428711","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Validation of the Chronic Liver Disease Questionnaire for MASH (CLDQ-MASH)","authors":"Zobair M. Younossi,&nbsp;Maria Stepanova,&nbsp;Issah Younossi,&nbsp;Andrei Racila","doi":"10.1016/j.jhepr.2024.101276","DOIUrl":"10.1016/j.jhepr.2024.101276","url":null,"abstract":"&lt;div&gt;&lt;h3&gt;Background &amp; Aims&lt;/h3&gt;&lt;div&gt;The new nomenclature for metabolic dysfunction-associated steatohepatitis (MASH) requires presence of steatohepatitis in the context of at least one cardiometabolic risk. Having a health-related quality of life (HRQL) instrument validated specifically in patients with MASH is important for clinical research and clinical trials.&lt;/div&gt;&lt;/div&gt;&lt;div&gt;&lt;h3&gt;Methods&lt;/h3&gt;&lt;div&gt;From our non-alcoholic fatty liver disease/non-alcoholic steatohepatitis (NAFLD/NASH) database, patients who met the definition of MASH according to the new criteria were selected. Subjects had completed the Chronic Liver Disease Questionnaire for NAFLD/NASH (CLDQ-NAFLD/NASH) and other HRQL instruments (Functional Assessment of Chronic Illness Therapy – Fatigue [FACIT-F], Short-Form 36 [SF-36]), and had available clinico-laboratory data including fibrosis non-invasive tests (NITs). The CLDQ-MASH was developed following a standard pipeline and subsequently validated in a non-overlapping sample.&lt;/div&gt;&lt;/div&gt;&lt;div&gt;&lt;h3&gt;Results&lt;/h3&gt;&lt;div&gt;There were 4,213 MASH patients included: age 56 ± 11 years, 44% male, 65% type 2 diabetes, 69% advanced fibrosis (F3–F4). The patients with MASH were split 1:2 into a training set used for development of CLDQ-MASH and a testing set used for validation using standard pipeline. After item reduction and exploratory factor analysis with the training set (&gt;90% variance), the CLDQ-MASH contained 35 items and seven domains. With the non-overlapping testing set, CLDQ-MASH demonstrated excellent face validity, internal consistency (all Cronbach’s alpha &gt;0.78), and high correlations with relevant domains of SF-36, FACIT-F (&lt;em&gt;p&lt;/em&gt; &lt;0.01). Known-groups validity assessment confirmed that CLDQ-MASH can discriminate patients based on liver disease severity (histology- and NIT-based) and the presence of non-hepatic comorbidities (obesity, type 2 diabetes, depression, clinically overt fatigue, insomnia). In a subsample of subjects with 1-year follow-up, the instrument was responsive to changes in Enhanced Liver Fibrosis® scores and liver stiffness measurements (&lt;em&gt;p&lt;/em&gt; &lt;0.05 for four to six domains).&lt;/div&gt;&lt;/div&gt;&lt;div&gt;&lt;h3&gt;Conclusions&lt;/h3&gt;&lt;div&gt;The CLDQ-MASH can be used as a valid disease-specific HRQL instrument for patients with MASH.&lt;/div&gt;&lt;/div&gt;&lt;div&gt;&lt;h3&gt;Impact and implications:&lt;/h3&gt;&lt;div&gt;The new criteria for metabolic dysfunction-associated steatohepatitis (MASH) are different from those previously used for non-alcoholic steatohepatitis so the evidence collected for the previous criteria need to be revisited, including disease-specific instruments for assessment of health-related quality of life. In patients with MASH, Chronic Liver Disease Questionnaire-MASH (CLDQ-MASH; 35 items, seven domains) has excellent psychometric properties including its internal consistency and various aspects of validity, and is responsive to changes in liver disease severity indicators. The CLDQ-MASH can be used as a valid disease-specific hea","PeriodicalId":14764,"journal":{"name":"JHEP Reports","volume":"7 3","pages":"Article 101276"},"PeriodicalIF":9.5,"publicationDate":"2024-11-16","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143180627","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}